Estrella Immunopharma Inc./$ESLA
1D1W1MYTD1Y5YMAX
Capital at risk
About Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
- Ticker
- $ESLA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- EmeryVille, United States
- Website
- www.estrellabio.com
ESLA Metrics
BasicAdvanced
$23M
-
-$0.25
0.89
-
Price and volume
Market cap
$23M
Beta
0.89
52-week high
$3.15
52-week low
$0.51
Average daily volume
36K
Financial strength
Current ratio
0.197
Quick ratio
0.016
Profitability
Effective tax rate (TTM)
0.00%
Management effectiveness
Return on assets (TTM)
-251.86%
Return on equity (TTM)
148.05%
Valuation
Price to book
-3.06
Price to tangible book (TTM)
-3.06
Price to free cash flow (TTM)
-2.256
Free cash flow yield (TTM)
-44.33%
Free cash flow per share (TTM)
-0.235
Growth
Earnings per share change (TTM)
-24.93%
Upcoming events
No upcoming events
ESLA News
AllArticlesVideos
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin's Lymphoma
Business Wire1 month ago
Estrella Immunopharma Announces First Patient Dosed in Dose-Expansion Phase of STARLIGHT-1 Trial and Reports Durable Response Rate in Advanced B-Cell Non-Hodgkin's Lymphoma
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.